SCHEDULE: John Lipman Discloses 9.99% Stake in ENDRA Life Sciences

John Carter Lipman has disclosed a 9.99% beneficial ownership stake in ENDRA Life Sciences Inc., primarily for passive investment purposes.

Summary

• John Carter Lipman reported beneficial ownership of 115,477 shares of ENDRA Life Sciences Inc. Common Stock.
• This ownership represents 9.99% of the company's outstanding Common Stock.
• The stake comprises 76,104 shares purchased directly and 39,373 shares issuable upon the exercise of Common Stock purchase warrants exercisable within 60 days.
• The percentage is calculated based on 1,166,441 shares of Common Stock issued and outstanding, as reported in ENDRA's preliminary Proxy Statement on Schedule 14A filed on October 17, 2025.
• The reporting person holds sole voting power and sole dispositive power over all 115,477 beneficially owned shares.
• The acquisition of these securities is for passive investment purposes and not with the intent to change or influence the control of ENDRA Life Sciences Inc.
• An additional 112,835 shares of Common Stock issuable upon warrant exercise are not included in the beneficial ownership calculation due to a 9.99% beneficial ownership limitation.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a significant individual investor has taken a substantial passive stake, which can be interpreted as a vote of confidence in the company's value, even if it's not an activist position.

Positives

• A significant individual investor, John Carter Lipman, has taken a 9.99% stake in ENDRA Life Sciences Inc., which can be interpreted as a vote of confidence in the company's value.
• The investment is explicitly stated to be for passive purposes, suggesting no immediate intent to disrupt management or operations.

Future Outlook

This filing does not provide any forward-looking statements or guidance from ENDRA Life Sciences Inc. or the reporting person regarding the company's future performance or strategic direction.

Industry Context

The disclosure of a significant passive stake by an individual investor like John Carter Lipman can sometimes signal external confidence in a company's long-term prospects within its industry. For a life sciences company such as ENDRA, such an investment might be viewed as a positive signal, especially if the investor has a track record in the sector, though this filing does not provide such details.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an individual investor may be viewed positively, potentially increasing market confidence and liquidity.
• Management: The passive nature of the investment suggests no immediate pressure for strategic changes, allowing management to continue current operations without direct influence from this specific shareholder.

Key Dates

Recommendation

While the disclosure of a significant passive stake by an individual investor can be a positive signal, a Schedule 13G filing primarily serves as a regulatory disclosure and does not provide sufficient information about the company's financial performance, strategic direction, or operational health to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental analysis or company-specific news.

Keywords

ENDRA Life Sciences, John Carter Lipman, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, Shareholder, Warrants